Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01949090 · ClinicalTrials.gov registry record · Phase 2
Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 363
- Enrollment target
NCT01949090 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 363 participants.
The verdict
NCT01949090, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 363 participants
- Enrollment target
Study Summary
The purpose of this placebo controlled study is to evaluate the safety and immunogenicity of different formulations of GSK Biologicals H7N1 influenza vaccine in subjects 65 years of age and older. The study will evaluate safety related events and antibody immune responses to different formulations of study vaccine.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Investigational H7N1 vaccine GSK2789869A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 363 participants |
| Start Date | 2013-09-25 |
| Est. Completion | 2014-10-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01949090
The ClinicalTrials.gov registry entry for NCT01949090 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 363 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01949090 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01949090 about?
NCT01949090 is a clinical study titled "Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older". The purpose of this placebo controlled study is to evaluate the safety and immunogenicity of different formulations of GSK Biologicals H7N1 influenza vaccine in subjects 65 years of age and older. The study will evaluate safety related events and antibody immune responses to different formulations o...
What is the current status of trial NCT01949090?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 363 participants. The study started on 2013-09-25. Estimated completion is 2014-10-23.
What interventions are being tested in trial NCT01949090?
The interventions under investigation include: Placebo (BIOLOGICAL), Investigational H7N1 vaccine GSK2789869A (BIOLOGICAL).
Who is sponsoring clinical trial NCT01949090?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.